The Experts below are selected from a list of 750 Experts worldwide ranked by ideXlab platform

Bruce A Mueller - One of the best experts on this subject based on the ideXlab platform.

  • ex vivo ceftolozane tazobactam clearance during Continuous renal replacement therapy
    Blood Purification, 2017
    Co-Authors: Weerachai Chaijamorn, Alexander R Shaw, Susan J Lewis, Bruce A Mueller
    Abstract:

    Background/Aims: To determine ceftolozane/tazobactam transmembrane clearances (CLTM) in Continuous hemofiltration (CHF) and Continuous Hemodialysis (CH

  • Ex vivo Ceftolozane/Tazobactam Clearance during Continuous Renal Replacement Therapy.
    Blood purification, 2017
    Co-Authors: Weerachai Chaijamorn, Alexander R Shaw, Susan J Lewis, Bruce A Mueller
    Abstract:

    Background/Aims: To determine ceftolozane/tazobactam transmembrane clearances (CLTM) in Continuous hemofiltration (CHF) and Continuous Hemodialysis (CH

  • Tedizolid clearance by in vitro Continuous renal replacement therapy model
    Critical Care, 2015
    Co-Authors: Susan J Lewis, Lynn A. Switaj, Bruce A Mueller
    Abstract:

    Tedizolid is an oxazolidinone antibiotic approved to treat acute bacterial skin and soft tissue infection and is under investigation for treatment of nosocomial pneumonia, common in critically ill patients with acute kidney injury. There are limited data on tedizolid disposition in Continuous renal replacement therapy (CRRT). This study's purpose was to assess Continuous hemofiltration (CHF) and Continuous Hemodialysis (CHD) influence on tedizolid clearance.

  • Telavancin and Hydroxy Propyl-β-Cyclodextrin Clearance during Continuous Renal Replacement Therapy: An in vitro Study:
    The International journal of artificial organs, 2009
    Co-Authors: Jignesh H. Patel, Mariann D. Churchwell, Julie D. Seroogy, Steven L. Barriere, Maricor Grio, Bruce A Mueller
    Abstract:

    BACKGROUND/AIMS Telavancin is a lipoglycopeptide antimicrobial agent which has been approved in Europe and has been recently FDA approved in the United States. Telavancin's parenteral solution contains hydroxy propyl-beta -cyclodextrin (HP-beta -CD) to enhance its solubility. The disposition of telavancin and HP-beta -CD during Continuous renal replacement therapies (CRRT ) has not been previously reported. METHODS The transmembrane clearances (CLtm ) of telavancin and HP-beta -CD during Continuous hemofiltration and Hemodialysis were assessed using an in vitro bovine blood model with AN69 and polysulfone hemodiafilters at varying ultrafiltrate and dialysate flow rates (1, 2, 3, & 6 l/hr). RESULTS The mean telavancin sieving coefficient ranged from 0.25 to 0.31 during Continuous hemofiltration. At all ultrafiltration rates, no differences were observed in telavancin CLtm between the two hemodiafilter types. For Continuous Hemodialysis, mean telavancin saturation coefficients ranged from 0.10 to 0.43 and CLtm tended to be higher for the polysulfone hemodiafilter than the AN69 hemodiafilter, especially at higher flow rates. Mean HP-beta -CD sieving coefficients ranged from 0.63 to 1.03 and saturation coefficients from 0.63 to 1.38, resulting in a CLtm that was similar to ultrafiltrate and dialysate flow rates. CONCLUSION Telavancin CLtm is dependent on hemodiafilter type, dialysate and ultrafiltration rates. CRRT with high ultrafiltrate or dialysate rates may result in sufficient telavancin clearance to alter telavancin dosing. HP-beta -CD clearance by Continuous Hemodialysis or Continuous hemofiltration is substantial and may be sufficient to prevent HP-beta -CD accumulation in subjects receiving CRRT . Pharmacokinetic studies conducted in patients receiving CRRT and telavancin are needed to confirm these in vitro findings.

  • Enhanced clearance of highly protein-bound drugs by albumin-supplemented dialysate during modeled Continuous Hemodialysis.
    Nephrology dialysis transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2008
    Co-Authors: Mariann D. Churchwell, Deborah A. Pasko, William E. Smoyer, Bruce A Mueller
    Abstract:

    Background.In2006,therewere16796toxicexposuresattributed to valproic acid (VPA), carbamazepine (CBZ) and phenytoin (PHT) reported to the US Toxic Exposure Surveillance System. Of these, 30% (5046) were treated in a health care facility with 12 cases resulting in death. Thesedrugsarehighlyproteinboundandpoorlydialyzable; however, it has been suggested that albumin-supplemented dialysate may enhance dialytic clearance. We investigated whether the addition of albumin to dialysate affects dialytic clearance of VPA, CBZ and PHT. Methods. VPA, CBZ and PHT were added to a bovine blood-basedinvitroContinuousHemodialysiscircuit,which included a polysulfone or an AN69 hemodialyzer. VPA, CBZ and PHT clearances were calculated from spent dialysate and pre-dialyzer plasma concentrations. VPA, CBZ and PHT clearances with control (albumin-free) dialysate were compared to clearances achieved with 2.5% or 5% human albumin-containing dialysate. The influences of blood flow (180 and 270 mL/min) and dialysate flow (1, 2 and 4 L/h) on dialysis clearance were also assessed. Results. The addition of 2.5% albumin to dialysate significantly enhanced dialytic clearance of VPA and CBZ, but not PHT. Use of 5% albumin dialysate further increased VPA and CBZ clearance. Overall, drug clearance was related directly to dialysate flow but independent of blood flow.

Jayan Nagendran - One of the best experts on this subject based on the ideXlab platform.

  • Continuous Hemodialysis Does Not Improve Graft Function During Ex Vivo Lung Perfusion Over 24 Hours
    Transplantation proceedings, 2019
    Co-Authors: Max T. Buchko, Sayed Himmat, Catherine J. Stewart, Sanaz Hatami, Peter Dromparis, Benjamin Adam, Darren H. Freed, Jayan Nagendran
    Abstract:

    Abstract Background Extended periods of ex vivo lung perfusion (EVLP) lead to several inadvertent consequences including accumulation of lactate and increasing electrolyte concentrations in the perfusate. We sought to determine whether Continuous Hemodialysis (CHD) of the perfusate would be a suitable modality for improving ionic homeostasis in extended EVLP without compromising functional outcomes. Methods Twelve porcine lungs were perfused using EVLP for 24 hours. All lungs were ventilated with negative pressure ventilation. Lungs in the treatment group (n = 6) underwent Continuous Hemodialysis of the perfusate. Functional parameters, edema formation, and histopathologic analysis were used to assess graft function. Electrolyte and lactate profiles were also followed to assess the efficiency of Hemodialysis. Results Lungs in both treatment and control groups demonstrated stable and acceptable oxygenation to 24 hours. Lungs demonstrated a decrease in compliance over time. There was no difference in oxygenation and compliance between groups. CHD-EVLP lungs had higher pulmonary vascular resistance and pulmonary artery pressures. Despite increased perfusion pressures, weight gain at both 11 and 23 hours was not different between groups. Perfusate sodium and lactate concentrations were significantly lower in the CHD-EVLP group. Conclusion The addition of Continuous Hemodialysis to EVLP did not improve graft function up to 24 hours despite improved maintenance of perfusate composition.

  • Continuous Hemodialysis during Ex Vivo Lung Perfusion Allows for Improved Maintenance of Perfusate Composition, without Compromising Functional Performance
    The Journal of Heart and Lung Transplantation, 2019
    Co-Authors: Max T. Buchko, Sayed Himmat, Catherine J. Stewart, Sanaz Hatami, Peter Dromparis, Benjamin Adam, Darren H. Freed, Jayan Nagendran
    Abstract:

    Purpose Extended periods of ex vivo lung perfusion (EVLP) lead to several inadvertent consequences including accumulation of lactate and increasing electrolyte concentrations in the perfusate. Cellular perfusate based systems, such as the OCS Lung and Vivoline LS1, require a membrane-exchange system for electrolyte correction if they are to maintain a desired perfusate hemoglobin concentration. We sought to determine whether Continuous Hemodialysis (CHD) of the perfusate would be a suitable modality for improving ionic homeostasis in extended EVLP without compromising functional outcomes. Methods Twelve porcine lungs were perfused using EVLP for 24 hours. Lungs in the treatment group (n=6) underwent Continuous Hemodialysis of the perfusate. Functional parameters, edema formation, inflammatory cytokines and histopathologic analysis were used to assess graft function. Electrolyte and lactate profiles were also followed to assess the efficiency of Hemodialysis. Results Lungs in both treatment and control groups demonstrated stable and acceptable oxygenation for 24 hours. Lungs demonstrated stable compliance over the first 18 hours, followed by a slow decline over the last 6 hours of perfusion. There was no difference in oxygenation and compliance between groups. CHD-EVLP lungs had higher pulmonary vascular resistance and pulmonary artery pressures. Despite increased perfusion pressures, weight gain at both 12 and 24 hours was not different between groups. Perfusate sodium and lactate concentrations were significantly lower in the CHD-EVLP group. TNF-α, IL-6, and IL-8 perfusate concentrations were similar between groups. Histopathologic assessment of lung injury did not differ between groups. Conclusion The addition of Continuous Hemodialysis to EVLP allows for stable functional performance up to 24 hours and improved physiologic perfusate composition despite increased perfusion pressures.

Susan J Lewis - One of the best experts on this subject based on the ideXlab platform.

Max T. Buchko - One of the best experts on this subject based on the ideXlab platform.

  • Continuous Hemodialysis Does Not Improve Graft Function During Ex Vivo Lung Perfusion Over 24 Hours
    Transplantation proceedings, 2019
    Co-Authors: Max T. Buchko, Sayed Himmat, Catherine J. Stewart, Sanaz Hatami, Peter Dromparis, Benjamin Adam, Darren H. Freed, Jayan Nagendran
    Abstract:

    Abstract Background Extended periods of ex vivo lung perfusion (EVLP) lead to several inadvertent consequences including accumulation of lactate and increasing electrolyte concentrations in the perfusate. We sought to determine whether Continuous Hemodialysis (CHD) of the perfusate would be a suitable modality for improving ionic homeostasis in extended EVLP without compromising functional outcomes. Methods Twelve porcine lungs were perfused using EVLP for 24 hours. All lungs were ventilated with negative pressure ventilation. Lungs in the treatment group (n = 6) underwent Continuous Hemodialysis of the perfusate. Functional parameters, edema formation, and histopathologic analysis were used to assess graft function. Electrolyte and lactate profiles were also followed to assess the efficiency of Hemodialysis. Results Lungs in both treatment and control groups demonstrated stable and acceptable oxygenation to 24 hours. Lungs demonstrated a decrease in compliance over time. There was no difference in oxygenation and compliance between groups. CHD-EVLP lungs had higher pulmonary vascular resistance and pulmonary artery pressures. Despite increased perfusion pressures, weight gain at both 11 and 23 hours was not different between groups. Perfusate sodium and lactate concentrations were significantly lower in the CHD-EVLP group. Conclusion The addition of Continuous Hemodialysis to EVLP did not improve graft function up to 24 hours despite improved maintenance of perfusate composition.

  • Continuous Hemodialysis during Ex Vivo Lung Perfusion Allows for Improved Maintenance of Perfusate Composition, without Compromising Functional Performance
    The Journal of Heart and Lung Transplantation, 2019
    Co-Authors: Max T. Buchko, Sayed Himmat, Catherine J. Stewart, Sanaz Hatami, Peter Dromparis, Benjamin Adam, Darren H. Freed, Jayan Nagendran
    Abstract:

    Purpose Extended periods of ex vivo lung perfusion (EVLP) lead to several inadvertent consequences including accumulation of lactate and increasing electrolyte concentrations in the perfusate. Cellular perfusate based systems, such as the OCS Lung and Vivoline LS1, require a membrane-exchange system for electrolyte correction if they are to maintain a desired perfusate hemoglobin concentration. We sought to determine whether Continuous Hemodialysis (CHD) of the perfusate would be a suitable modality for improving ionic homeostasis in extended EVLP without compromising functional outcomes. Methods Twelve porcine lungs were perfused using EVLP for 24 hours. Lungs in the treatment group (n=6) underwent Continuous Hemodialysis of the perfusate. Functional parameters, edema formation, inflammatory cytokines and histopathologic analysis were used to assess graft function. Electrolyte and lactate profiles were also followed to assess the efficiency of Hemodialysis. Results Lungs in both treatment and control groups demonstrated stable and acceptable oxygenation for 24 hours. Lungs demonstrated stable compliance over the first 18 hours, followed by a slow decline over the last 6 hours of perfusion. There was no difference in oxygenation and compliance between groups. CHD-EVLP lungs had higher pulmonary vascular resistance and pulmonary artery pressures. Despite increased perfusion pressures, weight gain at both 12 and 24 hours was not different between groups. Perfusate sodium and lactate concentrations were significantly lower in the CHD-EVLP group. TNF-α, IL-6, and IL-8 perfusate concentrations were similar between groups. Histopathologic assessment of lung injury did not differ between groups. Conclusion The addition of Continuous Hemodialysis to EVLP allows for stable functional performance up to 24 hours and improved physiologic perfusate composition despite increased perfusion pressures.

Pan Song-qi - One of the best experts on this subject based on the ideXlab platform.

  • Testosterone Undecanoate for Improving Quality of Life of Male Patients Undergoing Continuous Hemodialysis: A Randomized Controlled Trial
    Guangxi Medical Journal, 2014
    Co-Authors: Pan Song-qi
    Abstract:

    Objective To study the effectiveness,safety and tolerance of testosterone undecanoate( TU) in improving quality of life( QOL) of male patients undergoing Continuous Hemodialysis. Methods Seventy male patients undergoing Continuous Hemodialysis whose serum total testosterone( T) levels were lower than 9. 02 nmol / L were randomly divided into observation group and control group,with 35 cases in each group. The observation group was treated with routine Hemodialysis and TU( 80 mg / morning and 40 mg / night,and then 40 mg / morning and 40 mg / night after two weeks),the treatment lasted for 6 months. The control group was treated with routine Hemodialysis alone. The patients' QOL was assessed with WHOQOL-100 while their sexual function was assessed with the international index of erectile function( IIEF-5).Haemoglobin( Hb),prealbumin( PA),albumin( ALB),transferring( TRF),serum creatinine( Scr),serum testosterone( T) were measured. Results ① The levels of Hb,PA,ALB,TRF and T of observation group were significantly higher than those of control group 6 months after TU treatment( P 0. 05),but the levels of Scr,PSA showed no significant difference between two groups( P 0. 05). ② QOL scores in physiology,independence fields and total QOL scores of observation group were significantly higher than those of control group( P 0. 05),but other QOL scores showed no significant difference between two groups( P 0. 05). ③ IIEF scores of observation group were superior to those of control group( P 0. 05). ④ There were no significant differences in adverse effects( such as dysuria,lower extremity edema and so on) between two groups( P 0. 05). Conclusion TU can improve QOL,sexual function,anemia and nutritional status of male patients undergoing Continuous Hemodialysis significantly,with good safety and tolerance.